Pfizer Says Court Invalidates Celebrex Patent

Pfizer said a federal court has invalidated a reissue patent that would have offered an additional 18 months of U.S. exclusivity — and monopoly sales — to its blockbuster painkiller Celebrex.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news